US EditionWhy One Analyst Thinks LLY Is Worth $850 While the Rest of Wall Street Targets $1,216
Investor concerns rise over FDA review of Lilly's oral obesity pill and competitive pressure from Novo Nordisk amid a 5% stock drop and analyst downgrades.
4 Articles
4 Articles
Why Eli Lilly Stock Just Dropped
Key PointsHSBC analyst Rajesh Kumar downgraded Lilly stock to reduce this morning.Kumar believes GLP-1 demand, as measured in dollars, could be as little as half what other analysts forecast.10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) stock tumbled 5% through noon ET Tuesday. You can blame investment bank HSBC for that. HSBC, you see, just downgraded Lilly stock to sell. Will AI create the world's first trillionaire? Our team…
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Quick Read Eli Lilly (LLY) is down to the $937 area as investors await an April FDA decision on its oral obesity pill, orforglipron. Moreover, shares of Eli Lilly rival Novo Nordisk (NVO) are down 25% year to date as competition in the oral GLP-1 space intensifies. The LLY stock selloff reflects convergence of regulatory uncertainty around orforglipron approval timing combined with elevated pressure from Novo Nordisk. Are you ahead, or behin…
Major bank: Novo rival's optimistic outlook is not worth the moneyFor once, it's Eli Lilly that gets a downgrade thrown at the head of a major bank. British HSBC, the world's seventh largest
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
